X

Drug Profile

Research programme: tryptophan 2,3-dioxygenase inhibitors - iTeos Therapeutics

Latest Information Update: 28 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator iTeos Therapeutics
Developer iTeos Therapeutics; Ludwig Institute for Cancer Research
Class Small molecules
Mechanism of Action Tryptophan oxygenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Cancer

Most Recent Events

28 Mar 2023 Discontinued - Preclinical for Cancer in Belgium (unspecified route) (iTeos Therapeutics pipeline, March 2023)
28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in Belgium
08 Dec 2014 Tryptophan 2,3 dioxygenase inhibitors licensed to Pfizer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com